Pembrolizumab Shows Promise in Patients with Rare Form of Skin Cancer



In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the immunotherapy drug pembrolizumab.



Source link

Comments are closed.